Skip to main content
Erschienen in: International Journal of Hematology 6/2019

19.03.2019 | Original Article

Effects of low-dose combined oral contraceptives and protein S K196E mutation on anticoagulation factors: a prospective observational study

verfasst von: Takekazu Miyoshi, Hisato Oku, Saiko Asahara, Akira Okamoto, Koichi Kokame, Michikazu Nakai, Kunihiro Nishimura, Fumiyuki Otsuka, Aya Higashiyama, Jun Yoshimatsu, Toshiyuki Miyata

Erschienen in: International Journal of Hematology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

The association between low-dose combined oral contraceptives (COCs) and anticoagulation factors in Japanese women has been rarely studied. A total of 394 Japanese women with a new beginning cycle of COC use were enrolled, of whom 335 women visited the clinic within 4 weeks after starting the first cycle of COC. Visits occurred in the active phase (272 women) and the placebo phase (63 women). Free protein S (PS) antigen and activity levels and antithrombin activity levels decreased significantly in both the active and placebo phase groups. Protein C (PC) activity levels increased significantly in both groups. Larger reductions in free PS antigen and activity levels occurred with COC comprising either 30 µg ethinylestradiol/desogestrel or 20 µg ethinylestradiol/drospirenone than that comprising 35 µg ethinylestradiol/norethisterone. In four women with the Japanese-specific PS K196E mutation, mean PS activity was 65% before COC use and 57% during COC use, indicating further decrease with COC use. In conclusion, decreased antigen and activity levels of PS and antithrombin and increased activity levels of PC were observed even during the first cycle of low-dose COC use. The effects on PS and PC activities were also observed in the hormone-free interval.
Literatur
1.
Zurück zum Zitat de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;3:CD010813. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;3:CD010813.
2.
Zurück zum Zitat Sugiura K, Kobayashi T, Ojima T. Thromboembolism as the adverse event of combined oral contraceptives in Japan. Thromb Res. 2015;136:1110–5.CrossRefPubMed Sugiura K, Kobayashi T, Ojima T. Thromboembolism as the adverse event of combined oral contraceptives in Japan. Thromb Res. 2015;136:1110–5.CrossRefPubMed
3.
Zurück zum Zitat Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res. 2016;137:11–6.CrossRefPubMed Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res. 2016;137:11–6.CrossRefPubMed
4.
Zurück zum Zitat Hasegawa S, Matsui T, Hane Y, Abe J, Hatahira H, Motooka Y, et al. Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese adverse drug event report database. PLoS One. 2017;12:e0182045.CrossRefPubMedPubMedCentral Hasegawa S, Matsui T, Hane Y, Abe J, Hatahira H, Motooka Y, et al. Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese adverse drug event report database. PLoS One. 2017;12:e0182045.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.CrossRefPubMedPubMedCentral Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Hugon-Rodin J, Gompel A, Plu-Bureau G. Epidemiology of hormonal contraceptives-related venous thromboembolism. Eur J Endocrinol. 2014;171:R221–30.CrossRefPubMed Hugon-Rodin J, Gompel A, Plu-Bureau G. Epidemiology of hormonal contraceptives-related venous thromboembolism. Eur J Endocrinol. 2014;171:R221–30.CrossRefPubMed
7.
Zurück zum Zitat Grimes DA, Stuart GS, Levi EE. Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet Gynecol. 2012;120:889–95.CrossRefPubMed Grimes DA, Stuart GS, Levi EE. Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet Gynecol. 2012;120:889–95.CrossRefPubMed
8.
Zurück zum Zitat García de Frutos P, Fuentes-Prior P, Hurtado B, Sala N. Molecular basis of protein S deficiency. Thromb Haemost. 2007;98:543–56.CrossRefPubMed García de Frutos P, Fuentes-Prior P, Hurtado B, Sala N. Molecular basis of protein S deficiency. Thromb Haemost. 2007;98:543–56.CrossRefPubMed
9.
Zurück zum Zitat Hackeng TM, Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol. 2009;29:2015–20.CrossRefPubMed Hackeng TM, Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol. 2009;29:2015–20.CrossRefPubMed
10.
Zurück zum Zitat Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–7.CrossRefPubMed Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–7.CrossRefPubMed
11.
Zurück zum Zitat Miyata T, Kawasaki T, Fujimura H, Uchida K, Tsushima M, Kato H. The prothrombin gene G20210A mutation is not found among Japanese patients with deep vein thrombosis and healthy individuals. Blood Coagul Fibrinolysis. 1998;9:451–2.CrossRefPubMed Miyata T, Kawasaki T, Fujimura H, Uchida K, Tsushima M, Kato H. The prothrombin gene G20210A mutation is not found among Japanese patients with deep vein thrombosis and healthy individuals. Blood Coagul Fibrinolysis. 1998;9:451–2.CrossRefPubMed
12.
Zurück zum Zitat Yin T, Miyata T. Dysfunction of protein C anticoagulant system, main genetic risk factor for venous thromboembolism in northeast Asians. J Thromb Thrombolysis. 2014;37:56–65.CrossRefPubMed Yin T, Miyata T. Dysfunction of protein C anticoagulant system, main genetic risk factor for venous thromboembolism in northeast Asians. J Thromb Thrombolysis. 2014;37:56–65.CrossRefPubMed
13.
Zurück zum Zitat Liu W, Yin T, Okuda H, Harada KH, Li Y, Xu B, et al. Protein S K196E mutation, a genetic risk factor for venous thromboembolism, is limited to Japanese. Thromb Res. 2013;132:314–5.CrossRefPubMed Liu W, Yin T, Okuda H, Harada KH, Li Y, Xu B, et al. Protein S K196E mutation, a genetic risk factor for venous thromboembolism, is limited to Japanese. Thromb Res. 2013;132:314–5.CrossRefPubMed
14.
Zurück zum Zitat Miyata T, Maruyama K, Banno F, Neki R. Thrombophilia in East Asian countries: are there any genetic differences in these countries? Thromb J. 2016;14:25.CrossRefPubMedPubMedCentral Miyata T, Maruyama K, Banno F, Neki R. Thrombophilia in East Asian countries: are there any genetic differences in these countries? Thromb J. 2016;14:25.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kinoshita S, Iida H, Inoue S, Watanabe K, Kurihara M, Wada Y, et al. Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem. 2005;38:908–15.CrossRefPubMed Kinoshita S, Iida H, Inoue S, Watanabe K, Kurihara M, Wada Y, et al. Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem. 2005;38:908–15.CrossRefPubMed
16.
Zurück zum Zitat Kimura R, Honda S, Kawasaki T, Tsuji H, Madoiwa S, Sakata Y, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood. 2006;107:1737–8.CrossRefPubMed Kimura R, Honda S, Kawasaki T, Tsuji H, Madoiwa S, Sakata Y, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood. 2006;107:1737–8.CrossRefPubMed
17.
Zurück zum Zitat Ikejiri M, Wada H, Sakamoto Y, Ito N, Nishioka J, Nakatani K, et al. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol. 2010;92:302–5.CrossRefPubMed Ikejiri M, Wada H, Sakamoto Y, Ito N, Nishioka J, Nakatani K, et al. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol. 2010;92:302–5.CrossRefPubMed
18.
Zurück zum Zitat Jespersen J, Bertina RM, Haverkate F. ECAT assay procedures: a manual of laboratory techniques. Dordrecht: Kluwer Academic Publishers; 1992.CrossRef Jespersen J, Bertina RM, Haverkate F. ECAT assay procedures: a manual of laboratory techniques. Dordrecht: Kluwer Academic Publishers; 1992.CrossRef
19.
Zurück zum Zitat Miyata T, Sato Y, Ishikawa J, Okada H, Takeshita S, Sakata T, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res. 2009;124:14–8.CrossRefPubMed Miyata T, Sato Y, Ishikawa J, Okada H, Takeshita S, Sakata T, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res. 2009;124:14–8.CrossRefPubMed
20.
Zurück zum Zitat Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15–21.CrossRefPubMed Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15–21.CrossRefPubMed
21.
Zurück zum Zitat Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception. 2003;67:173–85.CrossRef Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception. 2003;67:173–85.CrossRef
22.
Zurück zum Zitat Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70:97–106.CrossRefPubMed Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70:97–106.CrossRefPubMed
23.
Zurück zum Zitat Suzuki A, Sanda N, Miyawaki Y, Fujimori Y, Yamada T, Takagi A, et al. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem. 2010;285:13444–53.CrossRefPubMedPubMedCentral Suzuki A, Sanda N, Miyawaki Y, Fujimori Y, Yamada T, Takagi A, et al. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem. 2010;285:13444–53.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Tay JW, Romeo G, Hughes QW, Baker RI. Micro-ribonucleic acid 494 regulation of protein S expression. J Thromb Haemost. 2013;11:1547–55.CrossRefPubMed Tay JW, Romeo G, Hughes QW, Baker RI. Micro-ribonucleic acid 494 regulation of protein S expression. J Thromb Haemost. 2013;11:1547–55.CrossRefPubMed
26.
Zurück zum Zitat van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.CrossRefPubMedPubMedCentral van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Kimura R, Sakata T, Kokubo Y, Okamoto A, Okayama A, Tomoike H, et al. Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers. J Thromb Haemost. 2006;4:2010–3.CrossRefPubMed Kimura R, Sakata T, Kokubo Y, Okamoto A, Okayama A, Tomoike H, et al. Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers. J Thromb Haemost. 2006;4:2010–3.CrossRefPubMed
28.
Zurück zum Zitat van Sluis GL, Söhne M, El Kheir DY, Tanck MW, Gerdes VE, Büller HR. Family history and inherited thrombophilia. J Thromb Haemost. 2006;4:2182–7.CrossRefPubMed van Sluis GL, Söhne M, El Kheir DY, Tanck MW, Gerdes VE, Büller HR. Family history and inherited thrombophilia. J Thromb Haemost. 2006;4:2182–7.CrossRefPubMed
29.
Zurück zum Zitat Bergendal A, Persson I, Odeberg J, Sundström A, Holmström M, Schulman S, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol. 2014;124:600–9.CrossRefPubMed Bergendal A, Persson I, Odeberg J, Sundström A, Holmström M, Schulman S, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol. 2014;124:600–9.CrossRefPubMed
30.
Zurück zum Zitat Miyata T, Kimura R, Kokubo Y, Sakata T. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. Int J Hematol. 2006;83:217–23.CrossRefPubMed Miyata T, Kimura R, Kokubo Y, Sakata T. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. Int J Hematol. 2006;83:217–23.CrossRefPubMed
31.
Zurück zum Zitat Sabra A, Bonnar J. Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel. J Reprod Med. 1983;28:85–91.PubMed Sabra A, Bonnar J. Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel. J Reprod Med. 1983;28:85–91.PubMed
32.
Zurück zum Zitat Winkler UH. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review. Am J Obstet Gynecol. 1998;179:51–61.CrossRef Winkler UH. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review. Am J Obstet Gynecol. 1998;179:51–61.CrossRef
33.
Zurück zum Zitat Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. Effects on hemostasis. Expert Rev Clin Pharmacol. 2017;10:1129–44.CrossRefPubMed Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. Effects on hemostasis. Expert Rev Clin Pharmacol. 2017;10:1129–44.CrossRefPubMed
34.
Zurück zum Zitat Ikejiri M, Wada H, Yamada N, Nakamura M, Fujimoto N, Nakatani K, et al. High prevalence of congenital thrombophilia in patients with pregnancy-related or idiopathic venous thromboembolism/pulmonary embolism. Int J Hematol. 2017;105:272–9.CrossRefPubMed Ikejiri M, Wada H, Yamada N, Nakamura M, Fujimoto N, Nakatani K, et al. High prevalence of congenital thrombophilia in patients with pregnancy-related or idiopathic venous thromboembolism/pulmonary embolism. Int J Hematol. 2017;105:272–9.CrossRefPubMed
35.
Zurück zum Zitat Kozuka T, Tamura S, Kawamura N, Nakata Y, Hasebe R, Makiyama A, et al. Progestin isoforms provide different levels of protein S expression in HepG2 cells. Thromb Res. 2016;145:40–5.CrossRefPubMed Kozuka T, Tamura S, Kawamura N, Nakata Y, Hasebe R, Makiyama A, et al. Progestin isoforms provide different levels of protein S expression in HepG2 cells. Thromb Res. 2016;145:40–5.CrossRefPubMed
36.
Zurück zum Zitat Miyata T, Hamasaki N, Wada H, Kojima T. More on: racial differences in venous thromboembolism. J Thromb Haemost. 2012;10:319–20.CrossRefPubMed Miyata T, Hamasaki N, Wada H, Kojima T. More on: racial differences in venous thromboembolism. J Thromb Haemost. 2012;10:319–20.CrossRefPubMed
37.
Zurück zum Zitat Adachi T, Sakamoto S. Thromboembolism during hormone therapy in Japanese women. Semin Thromb Hemost. 2005;31:272–80.CrossRefPubMed Adachi T, Sakamoto S. Thromboembolism during hormone therapy in Japanese women. Semin Thromb Hemost. 2005;31:272–80.CrossRefPubMed
38.
Zurück zum Zitat Maruyama K, Akiyama M, Kokame K, Sekiya A, Morishita E, Miyata T. ELISA-based detection system for protein S K196E mutation, a genetic risk factor for venous thromboembolism. PLoS One. 2015;10:e0133196.CrossRefPubMedPubMedCentral Maruyama K, Akiyama M, Kokame K, Sekiya A, Morishita E, Miyata T. ELISA-based detection system for protein S K196E mutation, a genetic risk factor for venous thromboembolism. PLoS One. 2015;10:e0133196.CrossRefPubMedPubMedCentral
Metadaten
Titel
Effects of low-dose combined oral contraceptives and protein S K196E mutation on anticoagulation factors: a prospective observational study
verfasst von
Takekazu Miyoshi
Hisato Oku
Saiko Asahara
Akira Okamoto
Koichi Kokame
Michikazu Nakai
Kunihiro Nishimura
Fumiyuki Otsuka
Aya Higashiyama
Jun Yoshimatsu
Toshiyuki Miyata
Publikationsdatum
19.03.2019
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 6/2019
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02633-x

Weitere Artikel der Ausgabe 6/2019

International Journal of Hematology 6/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.